Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Colleen M. Kusy
BAIRD
Colleen M. Kusy
Robert W. Baird
Wall Street Analyst
★★★☆☆
#1750
on 13Foresight · ranked by our own returns
37%
Success Rate
+6.4%
Average Return
7 of 19 calls profitable · -5.5% vs benchmark
📈 Across the calls we could measure, roughly 37% of Colleen M. Kusy's ratings turned a profit when each position was held for 1 year — averaging +6.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

16 Buy 10 Hold 0 Sell
Colleen's Stock Coverage 19 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
OCUL
Ocular Therapeutix
 Jun 18, 2026 BUY Strong Buy
+160.4% avg upside
21 analysts
$30.00
218.08% Upside
 ·
NUVL
Nuvalent
 Jun 09, 2026 HOLD Buy
-0.3% avg upside
21 analysts
$122.85
0.45% Downside
 +0.1%
OCS
Oculis Holding
 Jun 01, 2026 BUY Strong Buy
+241.9% avg upside
11 analysts
$38.00
238.64% Upside
 -22.1%
CLYM
Climb Bio
 May 06, 2026 BUY Strong Buy
+57.9% avg upside
18 analysts
$21.00
83.47% Upside
 -11.6%
SYRE
Spyre Therapeutics
 Apr 14, 2026 BUY Strong Buy
-15.4% avg upside
23 analysts
$90.00
1.93% Upside
 +30.6%
KPTI
Karyopharm Therapeutics
 Mar 25, 2026 BUY Strong Buy
+147.4% avg upside
18 analysts
$15.00
66.31% Upside
 +47.2%
IMMP
Immutep
 Mar 13, 2026 HOLD Strong Buy
+1343.0% avg upside
7 analysts
 — -8.3%
DNTH
Dianthus Therapeutics
 Mar 09, 2026 BUY Strong Buy
+8.8% avg upside
29 analysts
$132.00
60.09% Upside
 -0.4%
ARGX
Argenx Se
 Feb 27, 2026 HOLD Strong Buy
-15.9% avg upside
46 analysts
$867.00
1.14% Downside
 +15.1%
IOVA
Iovance Biotherapeutics
 Feb 25, 2026 HOLD Strong Buy
+225.8% avg upside
24 analysts
$4.00
2.37% Upside
 -9.9%
COGT
Cogent Biosciences
 Feb 19, 2026 HOLD Strong Buy
+7.1% avg upside
26 analysts
$35.00
1.25% Upside
 -10.7%
ELVN
Enliven Therapeutics
 Jun 16, 2025 BUY Strong Buy
+7.1% avg upside
14 analysts
$52.00
15.31% Upside
 +84.3%
AGEN
Agenus
 Jun 04, 2025 HOLD Strong Buy
+164.7% avg upside
17 analysts
$6.00
99.93% Upside
 -36.4%
ORIC
Oric Pharmaceuticals
 May 07, 2025 BUY Strong Buy
+180.3% avg upside
19 analysts
 — +87.5%
CHRS
Coherus Biosciences
 Dec 05, 2024 BUY Buy
+748.3% avg upside
18 analysts
$6.00
305.42% Upside
 -20.5%
EYPT
EyePoint Pharmaceuticals
 Nov 11, 2024 BUY Strong Buy
+123.7% avg upside
17 analysts
$33.00
142.93% Upside
 -2.9%
SABS
SAB Biotherapeutics
 Nov 15, 2022 BUY Strong Buy
+161.3% avg upside
13 analysts
$4.00
0.06% Downside
 -14.1%
GNCAQ
Genocea Biosciences
 Apr 10, 2022 BUY Strong Buy
+573999900.0% avg upside
10 analysts
$3.00
299999899.96% Upside
 ·
SNDX
Syndax Pharmaceuticals
 Jun 03, 2021 BUY Strong Buy
+88.8% avg upside
27 analysts
$31.00
63.08% Upside
 -8.0%
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Colleen M. Kusy — Frequently Asked Questions
How accurate are Colleen M. Kusy's stock ratings?
Based on the calls 13Foresight could measure, about 37% of Colleen's ratings were profitable over a one-year hold, with an average return of +6.4% per rating, or -5.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Colleen ranked on 13Foresight?
Colleen M. Kusy is currently ranked #1750 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Colleen cover?
Colleen most recently has ratings on OCUL, NUVL, OCS, CLYM, SYRE, KPTI, IMMP, DNTH, ARGX, IOVA, COGT, ELVN and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.